Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urologic Diseases 1Urinary Retention 1Urinary Bladder Neoplasms 1Thrombocytopenia 1Prostatic Neoplasms 1Patient Satisfaction 1Neoplasms 1Hemostatic Disorders 1Hemorrhage 1Hematuria 1

Interventions

Docetaxel 33Prednisone 28enzalutamide 19Abiraterone Acetate 13pembrolizumab 11gallium 68 PSMA-11 9Leuprolide 9Radiotherapy 8Pluvicto 8Magnetic Resonance Spectroscopy 8Nivolumab 7Estramustine 7abiraterone 6Radiotherapy, Intensity-Modulated 6Goserelin 6Carboplatin 6Biopsy 6olaparib 5cemiplimab 5bicalutamide 5Specimen Handling 5Paclitaxel 5Cyclophosphamide 5temsirolimus 4orteronel 4darolutamide 4cabazitaxel 4acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 4Sirolimus 4Radiosurgery 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Prostatic Neoplasms × Tranexamic Acid × Clear all
NCT04555343 2021-11-05

Intravesical Antifibrinolytic for Patients With Hematuria and Clot Retention

Fraser Health

Phase 1/2 Completed
14 enrolled
Genitourinary

Urinary Bladder Neoplasms, Hematuria, Prostatic Neoplasms, Urologic Diseases, Urinary Retention, Patient Satisfaction

Data powered by HemOnc (CC BY 4.0) Colophon âš¡